Faruqi & Faruqi Investigates Securities Fraud at Picard Medical

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Feb 04 2026

0mins

PMI0%

Should l Buy PMI?

Source: Globenewswire

Securities Fraud Investigation: Faruq & Faruqi LLP is investigating Picard Medical for potential violations of federal securities laws between September 2 and October 31, 2025, which may have caused significant investor losses, with a deadline of April 3, 2026, for investors to seek lead plaintiff status.
Stock Price Plunge: On October 24, 2025, shares of Picard Medical plummeted from $13.20 to $5.31, representing a $7.89 drop or approximately 59.8%, marking one of the most significant single-day declines since the company's IPO.
False Promotion Allegations: The complaint alleges that Picard and its executives engaged in a fraudulent stock promotion scheme involving misinformation on social media and failed to disclose insider trading activities, severely impacting investor decision-making.
Legal Rights Reminder: Faruq & Faruqi encourages investors with information regarding Picard Medical's conduct to contact the firm, assuring that all communications will be treated confidentially to provide legal support for affected investors.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PMI

About PMI

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Class Action Lawsuit Reminder Against Picard Medical, Inc.

5 hours agoGlobenewswire

Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between September 2, 2025, and October 31, 2025, with a deadline to contact the firm by April 3, 2026.
False Statements Allegation: The complaint alleges that Picard made false and misleading statements during the class period, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in significant losses for investors once the truth was revealed.
Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and representing investors globally, highlighting the importance of participation in the legal process.
Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or email to understand their rights and the steps to participate in the class action, ensuring they receive necessary legal support before class certification.

Picard Medical Securities Class Action Notice Issued

1 day agoGlobenewswire

Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements during the class period, failing to disclose significant adverse facts about its business and securities trading, which led to investor losses.
Fraudulent Activities Uncovered: Specific allegations include involvement in a fraudulent stock promotion scheme via social media misinformation and insiders using offshore accounts to manipulate share prices, severely impacting investor perceptions of the company's prospects.
Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.

Faruqi & Faruqi Investigates Securities Fraud Claims Against Picard Medical

2 days agoPRnewswire

Securities Fraud Investigation: Faruqi & Faruqi LLP is investigating potential securities fraud claims against Picard Medical, urging investors who suffered losses between September 2 and October 31, 2025, to seek lead plaintiff status by the April 13, 2026 deadline, thereby providing legal support for affected investors.
Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a staggering drop of $7.89 or approximately 59.8% in a single day, marking one of the most significant declines since the company's IPO, reflecting severe market concerns about its financial health.
False Promotion Allegations: The lawsuit alleges that Picard Medical and its executives violated federal securities laws through false statements and failure to disclose risks associated with a fraudulent stock promotion scheme, which may expose investors to significant losses and intensify scrutiny over the company's governance practices.
Legal Action Opportunity: Faruqi & Faruqi encourages all individuals with information regarding Picard Medical's conduct, including whistleblowers and former employees, to contact the firm to support the ongoing class action lawsuit, ensuring that all affected investors can seek the legal remedies they deserve.

Multiple Companies Face Class Action Lawsuits

3 days agoGlobenewswire

Richtech Robotics Lawsuit: Richtech Robotics Inc. is facing allegations of false statements during the class period from January 27 to January 29, 2026, claiming a partnership with Microsoft that did not exist, potentially misleading investors about the company's prospects and affecting stock performance.
Plug Power Lawsuit: Plug Power, Inc. is accused of making misleading statements from January 17 to November 13, 2025, overstating the likelihood of receiving DOE loan funds, which may force the company to pivot to smaller projects, thereby impacting future growth potential.
Picard Medical Lawsuit: Picard Medical, Inc. is implicated in a fraudulent stock promotion scheme from September 2 to October 31, 2025, involving misinformation and insider trading, which severely undermines investor confidence and the company's reputation.
BlackRock TCP Capital Lawsuit: BlackRock TCP Capital Corp. faces allegations of failing to appropriately value investments from November 6, 2024, to January 23, 2026, leading to understated unrealized losses and overstated net asset value, potentially causing significant investor losses.

Class Action Filed Against Picard Medical for Securities Fraud

4 days agoPRnewswire

Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Picard Medical, alleging that the company and certain executives engaged in securities fraud or other unlawful business practices, with investors having until April 3, 2026, to apply as Lead Plaintiff.
Stock Price Surge: Leading up to October 23, 2025, Picard's stock price skyrocketed from its IPO price of $4.00 per share to an all-time high of $13.68 per share, despite the absence of any fundamental news to justify such a dramatic increase.
Social Media Manipulation: Investigations have revealed that Picard's stock was subject to an illicit social media promotion scheme, where impersonators posing as legitimate financial advisors made sensational but unfounded claims, creating a buying frenzy among retail investors that artificially inflated the stock price.
Law Firm's Reputation: Pomerantz LLP is recognized as a leading firm in class action litigation, focusing on corporate and securities law, with over 85 years of experience in recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling such cases.